Renova Verification
- ✓≥99% purity by HPLC + mass spectrometry
- ✓Independent Janoshik 3rd-party analysis
- ✓−20°C lyophilized · 2–8°C reconstituted
← Back to catalog
Pérdida de Grasa & MetabolismAvailable
Retatrutide
10 mg / vial
🔬 Purity ≥99% · HPLC + MS🧪 Janoshik · 3rd-party🇺🇸 Made in a cGMP-compliant US lab
Triple agonist acting on GLP-1, GIP, and Glucagon receptors — the most advanced molecule in its class, currently in Phase III clinical trials.
- Mechanism: Triple agonist of GLP-1, GIP, and glucagon receptors (well-defined).
- Evidence: Strong in humans — published Phase 2 (NEJM, Nature Medicine) and Phase 3 readouts in 2026 (TRIUMPH-1 ~28% weight loss at 80 weeks; TRIUMPH-4 and type-2 diabetes positive); TRIUMPH-2/3 still to report.
- In context: GI effects; GLP-1s can affect fertility.
Presentation
$160 USD
💰 Buy by volume
3+ items
Save 5%
★ Wholesale
10+ of one
Save 15%
Discount applied automatically at checkout.
🧪 Per-batch COA❄️ Cold chain🛡️ Replacement guarantee🔒 Secure payment📦 Nationwide shipping🇺🇸 cGMP lab · per-batch COA
Research range · SC
1–12 mg · 1×/week (titrated)
🟢 Clinical evidence · titrated from a low dose
Ranges cited in research literature. Not a usage recommendation. For research use only.
🧪 Lab-verified: Janoshik Analytical · HPLC + MS · Purity ≥99%View COA →
This product is exclusively for research purposes. Not intended for human use, consumption, or therapeutic applications. For laboratory use only under qualified supervision.